Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.06 AUD | -3.23% | -14.29% | -15.49% |
Apr. 04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Sales 2022 | 5.43M 3.48M | Sales 2023 | 6.01M 3.86M | Capitalization | 12.57M 8.06M |
---|---|---|---|---|---|
Net income 2022 | -18M -11.55M | Net income 2023 | -15M -9.62M | EV / Sales 2022 | 7.95 x |
Net cash position 2022 | 13.85M 8.89M | Net cash position 2023 | 3.01M 1.93M | EV / Sales 2023 | 1.59 x |
P/E ratio 2022 |
-3.04
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.79% |
1 day | -3.23% | ||
1 week | -14.29% | ||
Current month | -10.45% | ||
1 month | -13.04% | ||
3 months | -14.29% | ||
6 months | -45.45% | ||
Current year | -15.49% |
Managers | Title | Age | Since |
---|---|---|---|
Gisela Mautner
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 19-02-28 | |
Olivier Laczka
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Bart
CHM | Chairman | 69 | 20-05-07 |
Peter Marks
BRD | Director/Board Member | 68 | 16-03-14 |
Boris Patkin
BRD | Director/Board Member | - | 20-03-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.06 | -3.23% | 215,468 |
24-04-18 | 0.062 | +3.33% | 12,401 |
24-04-17 | 0.06 | -5.51% | 486,889 |
24-04-16 | 0.0635 | -9.29% | 116,424 |
24-04-12 | 0.07 | +11.11% | 15,002 |
Delayed Quote Australian S.E., April 19, 2024 at 12:11 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-15.49% | 11.67M | |
-5.99% | 84.46B | |
+2.76% | 40.85B | |
-24.88% | 27.69B | |
+53.61% | 24.28B | |
-8.08% | 17.09B | |
-33.74% | 13.67B | |
-16.63% | 11.86B | |
-11.19% | 11.79B | |
-2.25% | 8.07B |
- Stock Market
- Equities
- NOX Stock